Human in Vivo Pharmacokinetics of [14C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing

详细信息    查看全文

• 作者：Erin Madeen ; Richard A. Corley ; Susan Crowell ; Kenneth Turteltaub ; Ted Ognibene ; Mike Malfatti ; Tammie J. McQuistan ; Mary Garrard ; Dan Sudakin ; David E. Williams
• 刊名：Chemical Research in Toxicology
• 出版年：2015
• 出版时间：January 20, 2015
• 年：2015
• 卷：28
• 期：1
• 页码：126-134
• 全文大小：317K
• ISSN：1520-5010

文摘

Dibenzo(def,p)chrysene (DBC), (also known as dibenzo[a,l]pyrene), is a high molecular weight polycyclic aromatic hydrocarbon (PAH) found in the environment, including food, produced by the incomplete combustion of hydrocarbons. DBC, classified by IARC as a 2A probable human carcinogen, has a relative potency factor (RPF) in animal cancer models 30-fold higher than benzo[a]pyrene. No data are available describing the disposition of high molecular weight (>4 rings) PAHs in humans to compare to animal studies. Pharmacokinetics of DBC was determined in 3 female and 6 male human volunteers following oral microdosing (29 ng, 5 nCi) of [¹⁴C]-DBC. This study was made possible with highly sensitive accelerator mass spectrometry (AMS), capable of detecting [¹⁴C]-DBC equivalents in plasma and urine following a dose considered of de minimus risk to human health. Plasma and urine were collected over 72 h. The plasma C_max was 68.8 卤 44.3 fg路mL^鈥? with a T_max of 2.25 卤 1.04 h. Elimination occurred in two distinct phases: a rapid (伪)-phase, with a T_1/2 of 5.8 卤 3.4 h and an apparent elimination rate constant (K_el) of 0.17 卤 0.12 fg路h^鈥?, followed by a slower (尾)-phase, with a T_1/2 of 41.3 卤 29.8 h and an apparent K_el of 0.03 卤 0.02 fg路h^鈥?. In spite of the high degree of hydrophobicity (log K_ow of 7.4), DBC was eliminated rapidly in humans, as are most PAHs in animals, compared to other hydrophobic persistent organic pollutants such as, DDT, PCBs and TCDD. Preliminary examination utilizing a new UHPLC-AMS interface, suggests the presence of polar metabolites in plasma as early as 45 min following dosing. This is the first in vivo data set describing pharmacokinetics in humans of a high molecular weight PAH and should be a valuable addition to risk assessment paradigms.